Literature DB >> 14151101

THE MACROMOLECULAR NATURE OF THE FIRST COMPONENT OF HUMAN COMPLEMENT.

G B NAFF, J PENSKY, I H LEPOW.   

Abstract

Kinetic and ultracentrifugal experiments demonstrated that the previously described subcomponents of human C'1, designated C'1q, C'1r, and C'1s, interacted with each other in liquid phase to form a macromolecule which was then capable of converting sensitized erythrocytes (EA) to the state EAC'1. The apparent sedimentation constants of C'1q, C'1r, and C'1s and of the macromolecular product of their interaction were approximately 11S, 7S, 4S, and 18S respectively. Association of C'1 subcomponents was prevented and dissociation of macromolecular C'1 was effected by Na(3)HEDTA and Na(2)MgEDTA but not by Na(2)CaEDTA. The rate of formation of macromolecular C'1 was a function of concentration of subcomponents and temperature of interaction, with an apparent energy of activation of 21,000 calories per mol. Ultracentrifugal studies further indicated the macromolecular nature of C'1 in normal human serum. In the absence of EDTA, C'1 sedimented with the serum macroglobulins and C'1 subcomponents were not detected. Conversely, in the presence of EDTA, macromolecular C'1 was not demonstrable and individual C'1 subcomponents could be measured in lighter fractions. The significance of these observations in relation to previous studies on C'1 subcomponents, the role of Ca(++) in C'1 function, and the subunit structure of Enzymes has been discussed.

Entities:  

Keywords:  BIOCHEMISTRY; CENTRIFUGATION; CHROMATOGRAPHY; COMPLEMENT; EDTA; HEAT; HEMOLYSIS; MACROMOLECULAR SYSTEMS; PHARMACOLOGY

Mesh:

Substances:

Year:  1964        PMID: 14151101      PMCID: PMC2137846          DOI: 10.1084/jem.119.4.593

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  STUDIES ON IMMUNE HUMAN HEMOLYSIS. III. ROLE OF 11 S COMPONENT IN INITIATING THE DONATH-LANDSTEINER REACTION.

Authors:  C F HINZ; A M MOLLNER
Journal:  J Immunol       Date:  1963-10       Impact factor: 5.422

2.  The tryptophan synthetase system.

Authors:  C YANOFSKY
Journal:  Bacteriol Rev       Date:  1960-06

3.  Isolation of a thermolabile serum protein which precipitates gamma-globulin aggregates and participates in immune hemolysis.

Authors:  H J MULLER-EBERHARD; H G KUNKEL
Journal:  Proc Soc Exp Biol Med       Date:  1961-02

4.  Partial purification of a serum inhibitor of C'1-esterase.

Authors:  J PENSKY; L R LEVY; I H LEPOW
Journal:  J Biol Chem       Date:  1961-06       Impact factor: 5.157

5.  A method for determining the sedimentation behavior of enzymes: application to protein mixtures.

Authors:  R G MARTIN; B N AMES
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

6.  Assay and properties of serum inhibitor of C'l-esterase.

Authors:  L R LEVY; I H LEPOW
Journal:  Proc Soc Exp Biol Med       Date:  1959 Aug-Sep

7.  Concerning the mechanism of complement action. II. The nature of the first component of guinea pig complement.

Authors:  E L BECKER
Journal:  J Immunol       Date:  1956-12       Impact factor: 5.422

8.  Observations on a pro-esterase associated with partially purified first component of human complement (C'1).

Authors:  I H LEPOW; O D RATNOFF; F S ROSEN; L PILLEMER
Journal:  Proc Soc Exp Biol Med       Date:  1956-05

9.  Studies on the mechanism of inactivation of human complement by plasmin and by antigen-antibody aggregates. I. The requirement for a factor resembling C'1 and the role of Ca++.

Authors:  I H LEPOW; L WURZ; O D RATNOFF; L PILLEMER
Journal:  J Immunol       Date:  1954-09       Impact factor: 5.422

10.  Some properties of an esterase derived from preparations of the first component of complement.

Authors:  O D RATNOFF; I H LEPOW
Journal:  J Exp Med       Date:  1957-08-01       Impact factor: 14.307

View more
  36 in total

1.  Human serum inhibits the interaction between C1q or rheumatoid factor and IgG-coated latex particles. Reduction of these C1-dependent properties after complement activation in vitro and in vivo.

Authors:  R Hällgren
Journal:  Immunology       Date:  1979-11       Impact factor: 7.397

2.  ACTION OF COMPLEMENT IN HEREDITARY ANGIONEUROTIC EDEMA: THE ROLE OF C'1-ESTERASE.

Authors:  V H DONALDSON; F S ROSEN
Journal:  J Clin Invest       Date:  1964-11       Impact factor: 14.808

3.  THE ELUTION OF S35-LABELLED C'1 FROM ANTIGEN-ANTIBODY-S35 COMPLEMENT PRECIPITATES.

Authors:  L KORNFELD; W O WEIGLE
Journal:  Immunology       Date:  1965-02       Impact factor: 7.397

4.  A C1-fixation method for the measurement of chicken anti-viral antibody.

Authors:  R L Stolfi; R A Fugmann; J J Jensen; M M Sigel
Journal:  Immunology       Date:  1971-03       Impact factor: 7.397

5.  Characterization of two different agglutinators in the latex fixation test, occurring in normal human sera.

Authors:  F Klein; H A Valkenburg; T L van Zwet; G J Lafeber
Journal:  Immunology       Date:  1966-01       Impact factor: 7.397

6.  Further studies on the chemotactic factor of complement and its formation in vivo.

Authors:  P A Ward; C G Cochrane; H J Muller-Eberhard
Journal:  Immunology       Date:  1966-08       Impact factor: 7.397

7.  C1r, subunit of the first complement component: purification, properties, and assay based on its linking role.

Authors:  M M De Bracco; R M Stroud
Journal:  J Clin Invest       Date:  1971-04       Impact factor: 14.808

8.  Reactive haemolysis--a distinctive form of red cell lysis.

Authors:  R A Thompson; D S Rowe
Journal:  Immunology       Date:  1968-05       Impact factor: 7.397

9.  In vitro activation of C1s in plasma of patients with hereditary angioneurotic oedema.

Authors:  S Shafiasghar; R H Cormane; K W Pondman
Journal:  Clin Exp Immunol       Date:  1976-08       Impact factor: 4.330

10.  Effect of C'1 esterase on vascular permeability in man: studies in normal and complement-deficient individuals and in patients with hereditary angioneurotic edema.

Authors:  M R Klemperer; V H Donaldson; F S Rosen
Journal:  J Clin Invest       Date:  1968-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.